

Open Access Journal by MDPI

Impact Factor 7.8 Indexed in PubMed CiteScore 7.0

Vaccines



mdpi.com/ journal/ vaccines



Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 11-year history of publishing peerreviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief Prof. Dr. Ralph A. Tripp

Aims

Vaccines is an international, peer-reviewed open access journal focused on laboratory and clinical vaccine research, utilization and immunization. It publishes reviews, research articles, case reports, etc. There is no restriction on the maximum length of papers. We encourage scientists to publish the results in as much detail as possible.

Scope

The scope of Vaccines includes:

- Immunology mechanisms
- Animal models for immunologic diseases
- Viral immunology
- Immunopathogenesis
- Vaccine developmentand efficacy evaluation
- Immune responses to vaccines
- Vaccine technology
- Vaccine vectors, adjuvants and immunomodulators
- Prophylactic vaccines, therapeutic vaccines, AIDS vaccines, gene vaccines, vaccines in bioterrorism
- Regulatory affairs, commercial utilization, safety

Author Benefits

Open Access

Unlimited and free access for readers

No Copyright Constraints

Retain copyright of your work and free use of your article

Thorough Peer-Review

2022 Impact Factor: 7.8

(Journal Citation Reports - Clarivate, 2023)

Discounts on Article Processing Charges (APC)

If you belong to an institute that participates with the MDPI Institutional Open Access Program

No Space Constraints, No Extra Space or Color Charges

No restriction on the maximum length of the papers, number of figures, or use of colors

Coverage by Leading Indexing Services

Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases

Rapid Publication

A first decision is provided to authors approximately 19.2 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the second half of 2023)

MDPI is a member of





















ORCID



Editorial Office

vaccines@mdpi.com

MDPI St. Alban-Anlage 66 4052 Basel, Switzerland Tel: +41 61 683 77 34 mdpi.com

